The discovery of an emerging viral disease, severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), has prompted the need to understand pathogenesis of SFTSV. We are unique in establishing an infectious model of SFTS in C57/BL6 mice, resulting in hallmark symptoms of thrombocytopenia and leukocytopenia. Viral RNA and histopathological changes were identified in the spleen, liver, and kidney. However, viral replication was only found in the spleen, which suggested the spleen to be the principle target organ of SFTSV. Moreover, the number of macrophages and platelets were largely increased in the spleen, and SFTSV colocalized with platelets in cytoplasm of macrophages in the red pulp of the spleen. In vitro cellular assays further revealed that SFTSV adhered to mouse platelets and facilitated the phagocytosis of platelets by mouse primary macrophages, which in combination with in vivo findings, suggests that SFTSV-induced thrombocytopenia is caused by clearance of circulating virus-bound platelets by splenic macrophages. Thus, this study has elucidated the pathogenic mechanisms of thrombocytopenia in a mouse model resembling human SFTS disease.
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animal model | phlebovirus | pathology | reduction of platelets | macrophage infection S evere fever with thrombocytopenia syndrome (SFTS) is a recently identified emerging viral infectious disease in China that is caused by a novel phlebovirus in the family Bunyaviridae, SFTS virus (SFTSV) (1) . Clinical features of SFTS patients include abrupt high fever, thrombocytopenia, leukocytopenia, and gastrointestinal symptoms. Laboratory tests commonly show elevated serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), lactate dehydrogenase, creatine kinase, creatine kinase MB fraction, as well as elongated activated partial-thromboplastin time (1) . These abnormally changed laboratory parameters are indicative of the pathological lesions that occur in multiple organs and altered homeostasis of the coagulation systems of SFTS patients. Pathological studies of SFTS are absent because patient tissues are rarely donated after death in rural areas of China. Therefore, the causes of illness and death, as well as pathological changes within organs, remain unclear. To systematically investigate the pathogenic mechanisms of SFTS and understand key symptoms, such as thrombocytopenia, infectious animal models for SFTSV are urgently needed.
Results
Establishment of a SFTSV Pathogenic Mouse Model. In our initial study, to identify an infectious animal model that could mimic most clinical features during SFTSV infection, the susceptibilities of three commonly used laboratory rodent strains for phlebovirus (2) (3) (4) , C57/BL6 mice, BalB/C mice, and Syrian hamsters, were examined. The SFTSV strain HB29 was inoculated at 10 5 TCID 50 (50% tissue culture infective dose) per mouse or 5 × 10 5 TCID 50 per hamster through four different routes of infection, including intravenous, intramuscular, intraperitoneal, and intracerebral injections. The results showed that in C57/BL6 mice, inoculation through all four routes induced a reduction of white blood cells, and the inoculation intravenously and intramuscularly induced a reduction of platelets (Fig. S1 ), but abnormal medical signs and weight loss were not observed. Inoculation of SFTSV to BalB/C mice or hamsters through all of the above routes could not cause significant changes in weight, white blood cell counts, and platelet counts. However, pathology examination on day 14 showed that all these SFTSV-infected rodents developed similar pathological lesions in liver and kidney [ Fig. 1 , representative pathology at day 14 postintion (p.i.) from C57/BL6 mice]. Based on a comprehensive evaluation, we determined that SFTSV-infected adult C57/ BL6 mice mimicked the major clinical features of leukocytopenia and thrombocytopenia in SFTS patients and, therefore, were selected for further investigations. Because SFTSV infection in the human is thought to be transmitted by tick bite (1), we chose intramuscular inoculation for subsequent animal studies.
Next, to thoroughly examine the complete disease progression of SFTSV infection in C57/BL6 mice, a group of 10 mice with intramuscular inoculation of 10 5 TCID 50 SFTSV per mouse and a group of 5 mock-infected mice were killed at each time point of days 1, 3, 7, 14, 21, and 28 p.i. for analysis of body weight, temperature, various laboratory parameters, and pathology. Similarly, as in initial studies, SFTSV inoculation caused significantly reduced platelet count on day 3 p.i., as well as reduced white blood cell count on day 1 and day 3 p.i. (Table 1) . Additionally, serum AST elevated on day 1 and lasted till day 7, and serum ALT and BUN elevated during 7-14 d (Table 1) . Therefore, we showed that intramuscular inoculation of SFTSV into C57/BL6 mice could induce symptoms that mimic the thrombocytopenia, leukocytopenia, and dysfunction in liver and kidney that are key clinical presentations of SFTS patients. However, fever and weight loss were not induced in SFTSV-infected C57/BL6 mice (Table 1) , and all tested mice survived. To evaluate if the immunocompromised animals could develop a more severe disease and even fatal outcome, we used immunosuppressive drug mitomycin C, which is known to inhibit the hematopoiesis in bone marrow (5) , to treat SFTSV-infected mice. We found that with mitomycin C application, 50% of the SFTSV-infected mice died between day 9 and day 10, and the remaining surviving mice experienced a significant loss of body mass compared with uninfected mice administered mitomycin C in parallel (Fig. S2) .
To define the infectious status of the immunecompetent mouse model, the dissemination and replication of SFTSV in blood and tissues were examined by detection of both viral RNA copies and infectious viral titers (1, 6) . The results showed that blood viral load peaked on day 1 p.i. and substantially decreased on day 3 p.i. (Table 1) . Dynamic virus distribution in eight tissues, including the spleen, liver, kidney, lung, intestine, heart, muscle, and brain, were also analyzed. Viral RNA was detected in three organs, including the spleen, liver and kidney, and the viral RNA copies per milligram of tissue in the spleen were significantly higher than in the liver or the kidney. Infectious viral titers were only detected in the spleen and kidney. This difference between the viral copies and infectious titers might be a result of the small amount of virus in liver being below the limit of detection for assays to determine infectious titers. We also noticed that there was a marked increase of viral load in spleen on day 3 p.i., and the virus RNA copies could be detected at a low level till to day 21 p.i. (Table 1 ). This finding suggested active viral replication occurred and remained at certain level in spleen. In the liver and kidney, the viral RNA copies initially were elevated on day 1 p.i. and then cleared by day 7 p.i. On the whole, the dynamic analysis of SFTSV dissemination in the blood and tissues showed that intramuscularly inoculated SFTSV entered the blood on day 1 p.i. and then were enriched in spleen on day 3 p.i., where the virus underwent a short term of replication, followed by clearance to a low level, thereafter. The sustained detection of low viral RNA copies in the spleen suggests a possible long-term harboring of SFTSV in spleen, contrasting the fast kinetics of viral clearance in other organs.
To further define immune responses induced by SFTSV infection in C57/BL6 mice, SFTSV-specific IgM and IgG antibodies in sera were tested by Luminex assays (7) . The data showed that SFTSV-specific IgM peaked on day 7 p.i., and the SFTSV-specific IgG started to increase on day 7 p.i. and peaked on day 28 p.i. (Table 1 ). The levels of neutralizing antibodies and splenic cellular responses in SFTSV-inoculated mice were significantly enhanced over mock-infected mice on day 28 p.i. (Table 1 ). This evidence of efficiently elevated humoral and cellular immune responses, combined with evidence of sustained viral replication in mice, support that C57/BL6 mice experienced a true infection with SFTSV and that they provide a useful parallel to SFTS patients for studying SFTSV pathogenesis.
The dose-dependent effect of SFTSV inoculation was also assessed by intramuscular inoculation of a low dose of 10 3 TCID 50 SFTSV per C57/BL6 mouse. Low dose of SFTSV did not induce a significant decrease of circulating platelets on day 3, but caused a significantly decreased white cell count on day 1 (Table S1) . Similarly, this low dose of SFTSV induced viremia on day 1, and the virus load peaked in spleen on day 3, but the levels of viral load were less than the levels observed in high dose of SFTSV infection (Table S1 ). Viral copies were hardly detected in liver or kidney tissue. Low-dose SFTSV induced similar levels of virus specific IgM and IgG as high dose of virus (Table 1) . Because a low dose of SFTSV induced insignificant clinical signs, low viral load, and high humoral immune responses, this finding suggests that the viral load is associated with the severity of the disease and that a low amount of SFTSV could result in an asymptomatic infection.
Pathological Lesions in SFTSV-Infected Mice. Pathological changes within organs were evaluated in the eight tissues indicated above, as well as in the bone marrow, by H&E staining of tissue samples collected at various time points postintramuscular inoculation. During SFTSV infection, pathological changes were mainly identified in the spleen and bone marrow within 3 d p.i. The lymphocyte cellularity of the red pulp was visually decreased in spleens of SFTSV infected mice during the first week after inoculation and gradually recovered 14 d later (Fig. 1A) . This observation of lymphocyte depletion in the red pulp may coincide with the systemic decrease of white blood cells. In addition, at an early stage of SFTSV infection, a marked increase of megakaryocytes was observed in the spleen, a secondary hemapoietic organ in mice, based on their cellular morphology (Fig. 1B) . This finding suggests extramedullary hematopoiesis, which has been reported to occur in conjunction with decreased lymphocyte cellularity of the red pulp (8) . Similarly, megakaryocytes in the bone marrow, the principle organ for hematopoiesis, also significantly increased at the early stage of infection as they did in the spleen (Fig. 1C) . Because megakaryocytes are progenitor cells for platelets, we presume that the rapid increase of megakaryocytes in the hemopoietic organs of the spleen and bone marrow functioned to compensate for the depletion of circulating platelets. Megakaryocytes have extended survival; therefore, once they have proliferated, they could persist in organs for a long period (9) . During the late phase of SFTSV infection, pathological changes were noted in liver and kidney. The primary lesions in liver consisted of ballooning degeneration of hepatocytes and scattered necrosis, the latter indicated by appearing multifocal pyknosis, karyorrhexis, and karyolysis (Fig. 1D) . TUNEL assays on liver tissues detected few TUNEL-positive nuclei, indicating that hepatocyte apoptosis was not induced. The kidney showed glomerular hypercellularity, mesangial thickening, and congestion in Bowman's space, but infiltration of inflammatory cells was absent (Fig. 1E ). Pathological changes within the liver and kidney tissues were maximal on day 14 p.i. but had nearly recovered on day 28 p.i. Therefore, the pathological features observed in the spleen and bone marrow during the early stage of infection were consistent with the hematological changes of thrombocytopenia and leukocytopenia.
The transient pathologic changes observed in kidney and liver at the later stage of infection were indicative of acute glomerular nephritis and acute hepatitis with self-limiting outcomes.
Identification and Colocalization of SFTSV, Macrophages, and Platelets
in the SFTSV-Infected Spleen. The findings that viral RNA was enriched in the spleen and that remarkable pathological changes occurred in the spleen during the early stage of infection suggested that the spleen was the primary target organ of SFTSV. Therefore, we performed an immunohistochemistry assay using a polyclonal antibody against SFTSV virions to detect target cells for viral replication, using spleens collected on day 3 p.i. The results showed that, in the spleen of SFTSV-infected mice, virus-positive cells were large monocytes, suggested by their large cytoplasm, lightly stained nuclei, and their scattered location throughout the red pulp ( Fig. 2A) . Immunehistochemistry staining for SFTSV was negative in bone marrow, kidney, liver, lung, gastrointestinal tract, heart, muscle, and brain. Based on the morphology and location of virus-positive monocytes in the spleen, macrophages were hypothesized to be the target cell of SFTSV. Therefore, splenic macrophages were identified by staining for the macrophagespecific membrane marker F4/80 (10). These results showed a substantially increased number of macrophages in the red pulp of the spleen on day 3 p.i. It is known that splenic macrophages are responsible for clearing old or impaired platelets from blood (11, 12) . Based on these observations, we hypothesized that the overwhelmingly increased number of macrophages appearing in the spleen function to clear platelets excessively from blood, resulting thrombocytopenia. We expected that, if this were the case, more platelets would be deposited in the spleens of SFTSV-infected mice. Therefore, splenic sections from tissues isolated day 3 p.i. were probed for platelets using an antibody against CD62P, an activation marker of platelets (11) . The results showed an increased deposition of CD62P + platelets in cytoplasm of the macrophage-like monocytes located in the red pulp of SFTSVinfected spleens ( Fig. 2A) , which coincided with increased macrophage density in the spleen.
To further clarify whether the SFTSV colocalized monocytes were macrophages and whether the increased splenic macrophages were engaged in platelet clearance, confocal microscopy was used to examine the colocalization of SFTSV, macrophages, and platelets. The results showed that almost all increased CD62P + platelets in spleen colocalized with F4/80 + macrophages and, moreover, SFTSV was found to colocalize with CD62P + platelets and F4/80 + macrophages in spleen (Fig. 2B) . Therefore, splenic macrophages were identified as target cells for SFTSV replication, and the increased numbers of splenic macrophages during the early stage of SFTSV infection appear to promote thrompocytopenia as a result of their responsibility of phagocytosing platelets.
SFTSV Adherence on Platelets Enhances Phagocytosis of Platelets by
Macrophages. To investigate the mechanistic interactions between SFTSV, platelets, and macrophages, mouse primary macrophages were used to test virus infection in vitro. The results showed that SFTSV could efficiently infect and replicate in mouse primary macrophages (Fig. 3A) . Because some Bunyaviruses have been reported to bind to platelets (13), we hypothesized that plateletbinding by SFTSV could promote their activation and phagocytosis by macrophages. To clarify this hypothesis, serially diluted SFTSV virions were cocultured with a fixed amount of mouse platelets, after which unbound virions were washed away. By using quantitative real-time PCR to determine viral copies in platelet pellets, a gradient of viruses were found to adhere on platelets corresponding to the serial dilutions (Fig. 3B, Left) . The virions that had adhered to platelets were further cultured in medium for studies to address their infectivity after platelet binding. Our results showed that the platelet-adherent virus dissociated into the supernatants after culturing for 1 d (Fig. 3B, Right) . Additionally, the total amount of virus detected in the platelets and supernatants did not increase over time, suggesting that no virus replication occurred in platelets. Moreover, mouse primary macrophages were mixed with mouse platelets that were previously cultured with or without SFTSV, respectively. After 30 min of culturing, macrophages were washed to remove unbound platelets. The results showed that, although normal platelets could adhere on the surface of uninfected macrophages, they were rarely internalized (Fig. 3C,  Top) . In contrast, platelets with adherent SFTSV were rapidly phagocytosed by uninfected macrophages (Fig. 3C, Middle) . The SFTSV-infected mouse macrophages did not show a significant difference in their phagocytosis of platelets (Fig. 3C, Bottom) . We also tested the macrophage phagocytosis of virus-adhered platelets using human macrophage cell line THP-1, differentiated by phorbol-12-myristate-13-acetate (11, 12, 14) . Similarly, we found that SFTSV could infect human THP-1 cells and adhered on human platelets. Furthermore, only SFTSV-adhered platelets but not normal platelets could be phagocytosed by THP-1 cells, and SFTSV-infected THP-1 cells were incapable of phagocytosing normal platelets (Fig. S3) . Therefore, the adherence of SFTSV on platelets is necessary for platelets to be phagocytosed by macrophages. Although we observed that macrophages could be directly infected by SFTSV, we expect that the phagocytosis of virus-decorated circulating platelets would deliver larger amounts of virus into macrophages than direct infection, while concurrently promoting the internalization of platelets.
Discussion SFTSV is a novel pathogenic phlebovirus in the Bunyaviridae family (1). Other pathogenic phleboviruses, such as rift valley fever virus (RVFV) and Punta Toro virus, mainly cause hepatic injury and viral antigens are detected in mouse liver lobe during the early stage of the infection (15) . In SFTSV-infected mice, the spleen was the principle target organ of SFTSV at the early infection stage, serving as a place for virus replication and showing marked pathological changes. In addition to the spleen, the liver and the kidney were also targeted by SFTSV. Although virus replication was not found in the liver or the kidney, elevated serum levels of AST, ALT, and BUN indicated dysfunction in these organs, and pathological changes were observed in the late phase of SFTSV infection that were consistent with the clinical presentation of elevated transaminases and renal symptoms of oliguria and anuria in SFTS patients. However, in this pathogenic mouse model, expected temperature elevations were not observed, and no lesions in the heart were observed, which was expected because some SFTS patients had elevated myocardial enzymes. Thus, using SFTSV infection of C57/BL6 mice, we have established a mouse model that mimics most major clinical features of SFTS patients, but still has certain limitations.
In our initial studies, we found SFTSV could induce reduction of white blood cells and platelets in C57/BL6 mice, but not in BalB/C mice or Syrian hamsters, which might be because of the varied genetic backgrounds of these rodent strains. In fact, several phleboviruses were reported to have selective susceptibility in animal hosts because of the existence of genetic determinants, such as during RVFV infection (16, 17) and Punta Toro virus infection (18) . Inoculation of virus through the subcutaneous and intramuscular routes have been commonly used for animal studies of bunyaviruses (4, 19, 20) . In our study, we observed that the effect of intramuscular injection of SFTSV was comparable to subcutaneous infection (Fig. S1) . Therefore, by testing various rodent strains and infection routes, we identified intramuscular infection of 10 5 TCID 50 SFTSV in C57/BL6 mice to be a model suitable for further investigation on pathogenesis of SFTSV infection.
Thrombocytopenia is a common clinical presentation of hematological changes during infections of viral hemorrhagic fever (VHF) viruses in family of Bunyaviridae. However, the mechanisms of thrombocytopenia in VHFs, and especially in bunyavirus infection, have been elusive. Possible mechanisms for bunyavirus-induced thrombocytopenia have been suggested to include increased platelet consumption in damaged tissues (13, 21, 22) , decreased survival time of platelets (23, 24) , or infection of megakaryocytes, resulting in decreased platelet production (23, 25) . Intriguingly, we found in this study that SFTSV colocalized with phagocytosed platelets in cytoplasm of splenic macrophages. Furthermore, using in vitro cellular assays, our data suggested that SFTSV could adhere on platelets and direct the platelets to be recognized and phagocytosed by macrophages in the red pulp of spleen. In support of this mechanism, we found that SFTSV antigen was not identified in bone marrow, and this excludes the possibility of decreased production of platelets by SFTSV-infected hematopoietic progenitor cells. We also excluded the possibility of increased platelet consumption in damaged tissues. During thrombocytopenia by this mechanism, platelets are activated through encounter with extracellular matrix, which is normally sequestered beneath an intact endothelium. Once activated, these platelets adhere to the extracellular matrix, resulting in platelet aggregation (26) and leading to decreased circulating platelets and increased deposition of platelets in tissues. However, our results showed that the plateletpositive staining was only localized to the spleen and not within other organs of SFTSV-infected mice. In this case, the decrease in circulating platelets during SFTSV infection is less likely to be a result of generalized deposition in tissues. Therefore, the enhanced clearance of virus-bound platelets promoted by splenic macrophages appears to be the major cause of thrombocytopenia in SFTSV-infected mice, which differs from the currently known mechanisms of bunyavirus-induced thrombocytopenia. It was reported that pathogenic hantaviruses, such as Andes virus or Hantaan virus, could bind quiescent platelets through β 3 integrin, and this binding promoted the adherence of platelets on endothelial cells (13) . However, so far it is not clear by which mechanism SFTSV-bound platelets are recognized and internalized by macrophages. Many VHF viruses in the bunyaviridae family, such as RVFV and Hantaan virus, can also infect monocytes/macrophages (27, 28) . Because monocytes are primary target cells for VHF viruses, these cells probably modulate either the spreading or containment of viral infection into cells in other organs. In this study, we found that SFTSV can infect and replicate in macrophages in vivo and in vitro, but the splenic viral load decreased to a low level later in infection. This finding suggests that although virus is capable of hijacking macrophages for replication, macrophages could also limit the growth of the virus and eventually clear the virus. Therefore, in immunocompetent individuals, SFTSV should be limited and cleared from the host. In contrast, when the immune system is impaired, the virus would be expected to efficiently proliferate in the host and result in multiorgan dysfunction and death. Along these lines, the most severe SFTS patients are the elderly (1), and some lethal SFTS cases have reported a history of early application of dexamethasone, which acts to repress immune functions (29) . In fact, in our study, weight loss and death were not observed in immunocompetent adult mice, but occurred in immunocompromised mice. Additionally, our finding that low-dose SFTSV infection results in reduced clinical severity compared with high dose of infection suggests that the virus amount is critical to disease severity. Combining of all these observations, it appears that an immunocompromised host that is unable to limit the replication of SFTSV and has high virus burden would be inclined to develop a severe disease status. Because SFTSV can directly infect macrophages and is harbored within splenic macrophages for long periods, the role of macrophages in limiting virus replication should be further investigated to clarify the potential pathogenic mechanisms of SFTSV and to understand how the host immune system limits virus replication.
The present study is unique in providing a reliable mouse model to investigate the pathogenesis of SFTSV infection and has demonstrated that pathological changes occur in three SFTSV-target organs, including the spleen, liver, and kidney, at early and late stages of the virus infection. In particular, this study has revealed splenic macrophages to be target cells for infection. Additionally, we have shown that macrophages likely are involved in the mechanism leading to thrombocytopenia, the major clinical hallmark symptom of SFTSV infection in humans. These findings relating to pathogenesis of SFTSV will help us better understand this new viral disease and open up the field for several lines of future studies.
Materials and Methods
SFTSV strain HB29 was isolated from a SFTS patient by plaque purification and obtained after five passages in Vero E6 cells. The SFTSV infectious animal experiments were conducted under biosafety level 3 (BSL3) containment in accordance with institutional guidelines. C57/BL6 mice (n = 10) were i.m. inoculated with 105 TCID50 SFTSV, and five mock mice were used in parallel as controls. At each time point, the rectal temperature and weight were acquired, then animals were exsanguinated and tissues were collected immediately. Taqman one-step real-time RT-PCR reactions were performed to test viral RNA copies in blood and tissues as previously described (6) . Infectious titers in blood and tissues were determined as previously reported (1, 20) . Luminex assay was used to quantify SFTSV-specific serum IgG and IgM antibodies. Neutralizing antibodies were tested by micro-serum neutralization test as previously described (1) . Serum AST and ALT were detected by ELISA kits (USCN Life Science Inc.), and BUN was detected by a Urea assay kit (Abcam) . Spenic cellular responses were tested by ELISPOT IFN-γ set analysis (BD). Pathological lesions were examined by H&E stained 4-μM thick paraffin-embedded tissue sections. Further, macrophage infection, platelet adherence, and macrophage phagocytosis of platelet assays were performed as previously described (11, 13) . Detailed description of above experiments, as well as the score system for pathological lesions and experimental procedures for immunohistochemistry and immunofluorescence are provided in SI Materials and Methods.
